IP Library Granted Patent US 12,419,909
Granted Patent B2
US 12,419,909 · App. 17/431,234 · Granted Sep 23, 2025

Hypochlorous acid intravenous solution, preparation, and method of use thereof

Inventor: Danyel Armando Arenas (Santander, CO)
Assignee: BIIOSMART TECHNOLOGIES LLC
A61K33/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,419,909
App. No.
17/431,234
Granted
Sep 23, 2025
Kind
B2
Abstract

Disclosed are intravenous solution compositions comprising hypochlorous acid (HOCl) suitable for systemic treatment or prevention of a variety of infections.

Claims (43)

1. A method of treating an infection, comprising providing an effective amount of an intravenous solution composition to a subject in need thereof, the intravenous solution composition comprises

about 0.010% to about 0.040% hypochlorous acid (HOCl);

about 0.05 to about 0.35% in NaCl;

about 0.005% to about 0.020% in OCl; and

water,

wherein all the % are by percentage over the total volume of the intravenous solution, and

wherein the composition has a pH of about 5.2 to about 6.2; and

wherein the intravenous solution composition is provided to the subject in an amount of about 1 to about 20 ml of the intravenous solution composition once per day for a total of about 4 to about 6 doses; or once every 48 hours for a total of about 4 to about 6 doses.

2. The method of claim 1 , wherein the infection to be treated is a bacterial infection, a fungal infection, a viral infection, a bacterial spore infection, a parasitic infection, or a combination thereof.

3. The method of claim 1 , wherein the hypochlorous acid intravenous solution is effective against antibiotic-resistant, antifungal-resistant, and antiviral-resistant species.

4. The method of claim 1 , wherein the infection is caused by gram negative bacteria, gram positive bacteria, Escherichia coli, Campylobacter rectus, Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Klebsiella oxytoca, Klebsiella pneumoniae, Staphylococcus aureus , methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, Salmonella enteritidis, Staphylococcus epidermidis, Streptococcus pyogenes, Treponema pallidum (syphilis), vancomycin-resistant enterococci, or a combination thereof;

Herpes simplex virus type-2 and type-1, human immunodeficiency virus (HIV), human papilloma virus (HPV), Hepatitis B and C virus, Bovine Diarrhea virus, molluscum contagiosum, respiratory viruses such as influenza viruses (e.g. H1N1), coronavirus, Zika virus, Ebola virus, or a combination thereof;

Aspergillus niger, Candida albicans, Trichophyton mentagrophytes , or a combination thereof; or

Trichomoniasis, leishmaniasis, or a combination thereof;

or a combination thereof.

5. The method of claim 1 , wherein the intravenous solution composition is further combined with a pharmaceutically acceptable intravenous vehicle, wherein the pharmaceutically acceptable intravenous vehicle is water for injection.

6. The method of claim 5 , wherein the intravenous solution composition is provided to the subject in an amount of about 1 to about 20 ml of the intravenous solution composition once per day for a total of about 4 to about 6 doses; or once every 48 hours for a total of about 4 to about 6 doses; and

wherein the intravenous solution composition is diluted in up to 100 ml of a pharmaceutically acceptable intravenous vehicle.

7. A method of augmenting the immune system of a subject, comprising providing an effective amount of the intravenous solution to a subject in need thereof, the intravenous solution composition comprises

about 0.010% to about 0.040% hypochlorous acid (HOCl);

about 0.05 to about 0.35% in NaCl;

about 0.005% to about 0.020% in OCl; and

water,

wherein all the % are by percentage over the total volume of the intravenous solution, and

wherein the composition has a pH of about 5.2 to about 6.2; and

wherein the intravenous solution composition is provided to the subject in an amount of about 1 to about 20 ml of the intravenous solution composition once per day for a total of about 4 to about 6 doses; or once every 48 hours for a total of about 4 to about 6 doses.

8. The method of claim 7 , wherein the subject has an infectious disease, is at risk of contracting an infectious disease, is receiving cancer treatment, chemotherapy, radiation therapy, will undergo surgery, or a combination thereof.

9. A method of treating bacterial or fungal contamination, bacterial or fungal infection, or sepsis in a subject, comprising providing an effective amount of the intravenous solution composition to a subject in need thereof, the intravenous solution composition comprises

about 0.010% to about 0.040% hypochlorous acid (HOCl);

about 0.05 to about 0.35% in NaCl;

about 0.005% to about 0.020% in OCl; and

water,

wherein all the % are by percentage over the total volume of the intravenous solution, and

wherein the composition has a pH of about 5.2 to about 6.2; and

wherein the intravenous solution composition is provided to the subject in an amount of about 1 to about 20 ml of the intravenous solution composition once per day for a total of about 4 to about 6 doses; or once every 48 hours for a total of about 4 to about 6 doses.

10. A method for treating cancer in a subject, comprising providing an effective amount of the intravenous solution composition to a subject in need thereof, the intravenous solution composition comprises

about 0.010% to about 0.040% hypochlorous acid (HOCl);

about 0.05 to about 0.35% in NaCl;

about 0.005% to about 0.020% in OCl; and

water,

wherein all the % are by percentage over the total volume of the intravenous solution, and

wherein the composition has a pH of about 5.2 to about 6.2; and

wherein the intravenous solution composition is provided to the subject in an amount of about 1 to about 20 ml of the intravenous solution composition once per day for a total of about 4 to about 6 doses; or once every 48 hours for a total of about 4 to about 6 doses.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2021
From: ARENAS, DANYEL ARMANDO
To: BIIOSMART TECHNOLOGIES LLC
Reel/Frame 057188/0911 →
Continuity (2)
Provisional Application 62807787 · Feb 20, 2019
Related Publication 20220133779A1 · May 5, 2022
References Cited (46)
US 5731008A · Morrow · 1998 [cited by applicant]
US 7090753B2 · Sumita · 2006 [cited by applicant]
US 8367120B1 · Norton et al. · 2013 [cited by applicant]
US 8663705B2 · Norton et al. · 2014 [cited by applicant]
US 8728537B2 · Wannowius et al. · 2014 [cited by applicant]
US 8877257B2 · Goldan et al. · 2014 [cited by applicant]
US 8945630B2 · Calderon · 2015 [cited by applicant]
US 9168318B2 · Alimi · 2015 [cited by applicant]
US 9414584B2 · Panicheva et al. · 2016 [cited by applicant]
US 9486479B2 · Northey · 2016 [cited by applicant]
US 9642876B2 · Alimi · 2017 [cited by applicant]
US 9867849B2 · Lange et al. · 2018 [cited by applicant]
US 9918477B2 · Northey · 2018 [cited by applicant]
US 10016455B2 · Alimi · 2018 [cited by applicant]
US 10094030B2 · Rubinsky et al. · 2018 [cited by applicant]
US 20030185704A1 · Bernard et al. · 2003 [cited by applicant]
US 20060039996A1 · Palmer · 2006 [cited by applicant]
US 20070196357A1 · Alimi et al. · 2007 [cited by applicant]
US 20090258083A1 · Calderon · 2009 [cited by applicant]
US 20100166809A1 · Northey et al. · 2010 [cited by applicant]
US 20120207853A1 · Alimi et al. · 2012 [cited by applicant]
US 20120269904A1 · Northey · 2012 [cited by applicant]
US 20130115307A1 · Norton et al. · 2013 [cited by applicant]
US 20150119245A1 · Robertson, Jr. et al. · 2015 [cited by applicant]
US 20170296578A1 · Sampson et al. · 2017 [cited by applicant]
US 20180110803A1 · Paz Garcia et al. · 2018 [cited by applicant]
US 20180177824A1 · Almas · 2018 [cited by applicant]
US 20190216090A1 · Alimi et al. · 2019 [cited by applicant]
CN 101932330A · 2010 [cited by applicant]
KR 20050039835A · 2005 [cited by applicant]
WO 2014015444A1 · 2014 [cited by applicant]
WO 2019006217A1 · 2019 [cited by applicant]
CDC Risk Factors Fungal Disease 2024. [cited by examiner]
Extended European Search Report Search Report for Appl. No. 20759982.0-1112/3927351 PCT/US2020018966; Date of Mailing Dec. 6, 2022, 9 pages. [cited by applicant]
“Basic Chemisty of Chlorination”, Hydro Instruments, Jul. 2010, 8 pages. [cited by applicant]
Captain John Fraser et al., “Further Observations on the Treatment of Gas Gangrene by the Inravenous Injection of Hypochlorous Acid (Eusol)”, The British Medical Journal, Aug. 5, 1916, 3 pages. [cited by applicant]
Captain John Fraser et al., “Treatement of Acute Toxaemia Secondary to Gas Gangrene by the Intravenous Injection of a Solution of Hypochlorous Acid”, The British Medical Journal, Jan. 15, 1916, 4 pages. [cited by applicant]
David Armstrong et al., “Expert recommendations for the Use of Hypochlorous Solution: Science and Clinical Application”, Wounds:a compendium of clinical research and practice, May 2015, 20 pages. [cited by applicant]
Dmitri Debabov et al., “Avenova with Neutrox (pure 0.01% HOCLI) compared with OTC product (0.02% HOCI)”, NovaBay Pharmaceuticals, Inc., May 2015, 5 pages. [cited by applicant]
Eryilmaz, Mujde et al.; “Hypochlorous Acid—Analytical Methods and Antimicrobial Activity”; Tropical Journal of Pharmaceutical Research, V. 12:1, Feb. 2013, p. 123-126. [cited by applicant]
H.D. Dakin, “The Behaviour of Hypochlorites on Intravenous Injection and their Action on Blood Serum”, The British Medical Journal, Jun. 17, 1916, 3 pages. [cited by applicant]
International Search Report issued in Application No. PCT/US2020/018966 on May 15, 2020, 5 pages. [cited by applicant]
P.C. Vincent et al., “Evaluation of an Antitumor Cell Wound Irrigant-Milton, A Stable Hypochlorite”, Cancer, vol. 17, Aug. 1964, 9 pages. [cited by applicant]
Ronald W. Pero et al., “Hypochlorous acid/N-chloramines are naturally produced DNA repair inhibitors”, Carinogenesis, vol. 17, No. 1, 1996, 6 pages. [cited by applicant]
Shawnna Veasey et al., “Evaluation of Electrolytically-Generated Hypochlorous Acid (‘Electrolyzed Water’) for Sanitation of Meat and Meat-Contact Surfaces,” Foods, vol. 5, No. 42, Jun. 13, 2016, 15 pages. [cited by applicant]
Written Opinion issued in Application No. PCT/US2020/018966 on May 15, 2020, 7 pages. [cited by applicant]